How would the
liquid biopsy test
revolutionize cancer
diagnosis and
treatment?
Strand LB tests play a
critical role in cancer
diagnostics. The test is
beneficial to patients at
several stages – early
detection, review and
monitoring of non-
biopsiable tissue and
finally for regular
monitoring and review
post surgery.
In cancer treatment,
the thumb rule is that
prognosis of survival is
higher when the disease is
detected at an early stage.
A common example in the
case of breast cancer is
that stage one has almost
100% 5-year-survival rate
compared to stage four
which has a meager 22%
survival rate.
Liquid biopsy has
provided this opportunity
to the patient where
with the help of a simple
blood draw, diagnosis
can be made along with
identification of genetic
markers (EGFR, KRAS,
TP53). One challenge with
this technique is limited
tumor DNA present in
the blood.
Strand LB has been
able to overcome this by
developing the ability of
detecting one tumor DNA
molecule in 1000 normal
DNA fragments. The best-
in-class bioinformatics
capabilities also reduce
the output time to only 5
working days. This helps
the patient and physician
to be proactive when
making treatment choices
rather than reactive
and reduces the disease
and financial burden of
the patient.
In addition, some of
BIOVOICENEWS.COM
41